On Oct. 29, 2020, Mammoth Biosciences announced that it had signed agreements with MilliporeSigma and Hamilton Company targeting commercialization of a high-throughput CRISPR-based SARS CoV-2 test. The test leverages Mammothﾒs DETECTR BOOSTﾙ platform and will provide a sample-to-answer turnkey solution for commercial laboratories to enable a multi-fold increase in testing capacity.